Circulating Tumor Cell Chromosomal Instability and Neuroendocrine Phenotype by Immunomorphology and Poor Outcomes in Men with mCRPC Treated with Abiraterone or Enzalutamide
Abstract
While the detection of AR-V7 in circulating tumor cells (CTC) is associated with resistance to abiraterone or enzalutamide in men with metastatic castration-resistant prostate cancer (mCRPC), it only accounts for a minority of this resistance. Neuroendocrine (NE) differentiation or chromosomal instability (CIN) may be additional mechanisms that mediate resistance.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Apr 05, 2021
- Source ID
- 10.1158/1078-0432.ccr-20-3471
Entities
People
- Adam Jendrisak
- Andrew Armstrong
- Audrey Gill
- Daniel C. Danila
- Daniel J George
- David M. Nanus
- Emily A Carbone
- Emmanuel S. Antonarakis
- Ethan S. Barnett
- Howard I. Scher
- Jimmy L. Zhao
- Joseph D. Schonhoft
- Jun Luo
- Landon C Brown
- Monika Anand
- Paraskevi Giannakakou
- Patrick Healy
- Qian Yang
- Richard Wenstrup
- Russell Z. Szmulewitz
- Santosh K. Gupta
- Simon G. Gregory
- Susan Halabi
- William L Berry
Organizations
- Duke Cancer Institute
- Duke University
- Johns Hopkins University
- National Cancer Institute
- National Institutes of Health
- United States Department of Defense